Abbreviations
| 3TC |
lamivudine |
| ABC |
abacavir |
| ART |
antiretroviral therapy |
| ARV |
antiretroviral |
| AUC24 h |
24-hour area under the concentration–time curve |
| C24 h |
24-hour plasma concentration |
| CL |
clearance |
| CYP |
cytochrome 450 |
| DTG |
dolutegravir |
| EFV |
efavirenz |
| EMA |
European Medicines Agency |
| EU |
European Union |
| FDA |
United States Food and Drug Administration |
| FTC |
emtricitabine |
| HBV |
hepatitis B virus |
| HCV |
hepatitis C virus |
IMPAACT
|
International Maternal Pediatric Adolescent AIDS Clinical Trials |
| LPV/r |
lopinavir/ritonavir |
| NRTI |
nucleoside reverse-transcriptase inhibitor |
| PANNA |
Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women |
| PENPACT |
PENTA 9/PACTG 390 |
| PENTA |
Paediatric European Network for Treatment of AIDS |
| PEPFAR |
United States President’s Emergency Plan for AIDS Relief |
| TAF |
tenofovir alafenamide |
| TB |
tuberculosis |
| TDF |
tenofovir disoproxil fumarate |
| UGT |
uridine diphosphate-glucuronosyltransferase |
| UNICEF |
United Nations Children’s Fund |
| WT |
body weight |
Recognition
This toolkit is formally recognised for its quality and content by the following organisations and institutions:














For further information please contact: training@theglobalhealthnetwork.org